# Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema

> **NCT01189461** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 46 (actual)

## Conditions studied

- Anti- VGF Inhibitor
- Diabetic Macular Edema
- Diabetic Retinopathy

## Interventions

- **DRUG:** pegaptanib sodium

## Key facts

- **NCT ID:** NCT01189461
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2013-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01189461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01189461, "Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01189461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*